CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Apple Turns 50: From Garage Startup to AI Crossroads 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2016 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:NBI). GBT’s addition to the NBI will become effective upon market open on Monday, December 19, 2016.
The NASDAQ Biotechnology Index, which is re-ranked annually, is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). Companies in the NASDAQ Biotechnology Index must meet eligibility criteria, including a market capitalization of at least $200 million and an average daily trading volume of at least 100,000 shares. For more information about the NASDAQ Biotechnology Index, please visit https://indexes.nasdaqomx.com/docs/methodology_NBI.pdf.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease and has begun initiating clinical trial sites and screening patients for its Phase 3 clinical trial, also known as the HOPE Study. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis. To learn more, please visit: www.globalbloodtx.com.
Forward-Looking Statements
Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements, including statements regarding the therapeutic potential and safety profile of GBT440, our ability to implement our clinical development plans for GBT440, the timing of, and our ability to generate data from, our ongoing Phase 1/2 clinical trial of GBT440 and our ability to enroll patients in and begin screening in our HOPE Study, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, the risks that our clinical and preclinical development activities may be delayed or terminated for a variety of reasons, that regulatory authorities may disagree with our clinical development plans or require additional studies or data to support further clinical investigation of our product candidates, and that drug-related adverse events may be observed in later stages of clinical development, along with those risks set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2016, June 30, 2016 and September 30, 2016, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information: Myesha Lacy (investors) Global Blood Therapeutics 650-351-4730 [email protected] Julie Normart (media) BrewLife 415-946-1087 [email protected]
